Your browser doesn't support javascript.
loading
Hydroxysafflor Yellow A Inhibits Pyroptosis and Protecting HUVECs from OGD/R via NLRP3/Caspase-1/GSDMD Pathway.
Guo, Fan; Han, Xiao; You, Yue; Xu, Shu-Juan; Zhang, Ye-Hao; Chen, Yuan-Yuan; Xin, Gao-Jie; Liu, Zi-Xin; Ren, Jun-Guo; Cao, Ce; Li, Ling-Mei; Fu, Jian-Hua.
Affiliation
  • Guo F; Institute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.
  • Han X; Beijing Key Laboratory of Chinese Materia Pharmacology, Beijing, 100091, China.
  • You Y; Institute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.
  • Xu SJ; Beijing Key Laboratory of Chinese Materia Pharmacology, Beijing, 100091, China.
  • Zhang YH; Institute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.
  • Chen YY; Beijing Key Laboratory of Chinese Materia Pharmacology, Beijing, 100091, China.
  • Xin GJ; Institute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.
  • Liu ZX; Beijing Key Laboratory of Chinese Materia Pharmacology, Beijing, 100091, China.
  • Ren JG; Institute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.
  • Cao C; Beijing Key Laboratory of Chinese Materia Pharmacology, Beijing, 100091, China.
  • Li LM; Institute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.
  • Fu JH; Beijing Key Laboratory of Chinese Materia Pharmacology, Beijing, 100091, China.
Chin J Integr Med ; 2024 Feb 06.
Article in En | MEDLINE | ID: mdl-38319525
ABSTRACT

OBJECTIVE:

To observe the protective effect and mechanism of hydroxyl safflower yellow A (HSYA) from myocardial ischemia-reperfusion injury on human umbilical vein endothelial cells (HUVECs).

METHODS:

HUVECs were treated with oxygen-glucose deprivation reperfusion (OGD/R) to simulate the ischemia reperfusion model, and cell counting kit-8 was used to detect the protective effect of different concentrations (1.25-160 µ mol/L) of HSYA on HUVECs after OGD/R. HSYA 80 µ mol/L was used for follow-up experiments. The contents of inflammatory cytokines interleukin (IL)-18, IL-1 ß, monocyte chemotactic protein 1 (MCP-1), tumor necrosis factor α (TNF-α) and IL-6 before and after administration were measured by enzyme-linked immunosorbent assay. The protein expressions of toll-like receptor, NOD-like receptor containing pyrin domain 3 (NLRP3), gasdermin D (GSDMD) and GSDMD-N-terminal domain (GSDMD-N) before and after administration were detected by Western blot. NLRP3 inflammasome inhibitor cytokine release inhibitory drug 3 sodium salt (CRID3 sodium salt, also known as MCC950) and agonist were added, and the changes of NLRP3, cysteine-aspartic acid protease 1 (Caspase-1), GSDMD and GSDMD-N protein expressions were detected by Western blot.

RESULTS:

HSYA inhibited OGD/R-induced inflammation and significantly decreased the contents of inflammatory cytokines IL-18, IL-1 ß, MCP-1, TNF-α and IL-6 (P<0.01 or P<0.05). At the same time, by inhibiting NLRP3/Caspase-1/GSDMD pathway, HSYA can reduce the occurrence of pyroptosis after OGD/R and reduce the expression of NLRP3, Caspase-1, GSDMD and GSDMD-N proteins (P<0.01).

CONCLUSIONS:

The protective effect of HSYA on HUVECs after OGD/R is related to down-regulating the expression of NLRP3 inflammasome and inhibiting pyroptosis.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Chin J Integr Med Year: 2024 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Chin J Integr Med Year: 2024 Document type: Article